AC Immune SA (ACIU)
Develops antibody and diagnostic treatments targeting protein misfolding in Alzheimer's and Parkinson's diseases.
$2.32+0.01%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago+9.4%
The outlook
AC Immune is trading near the bottom of its 52-week range, well below its short and long-term moving averages. Analyst consensus is notably bullish, with an average price target implying significant upside from current levels. The overall picture reflects a stock under pressure, though supported by strong analyst backing.
What’s behind the score
Analyst consensusStrong Buy — 1.0 avg of 4 analysts
Price trendBelow its 50- & 200-day averages
52-week range15% of the way from its 52-week low to high
Price targetAvg target +266% vs current price
Analyst price target
~12-month · 4 analysts$8.50average target+266.4% vs now
Now $2.32
Low $5.32High $11.85
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$236.1M
52-wk high
$4.00
52-wk low
$2.03
50-day avg
$2.47
200-day avg
$2.94
Trailing P/E
—